Claudio Iannacone

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Vincent Rijckborst, Bettina E. Hansen, Péter Ferenci et al. · Journal of Hepatology · 2012 · 170 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Long‐term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open‐label, cohort study

Laura Gragnani, Elisa Fognani, A. Piluso et al. · Hepatology · 2014 · 131 citations · Full text

Pharmacy, Infectious Diseases, Microbiology +17

Prevalence of fatigue in Parkinson disease and its clinical correlates

Fabrizio Stocchi, Giovanni Abbruzzese, Roberto Ceravolo et al. · Neurology · 2014 · 129 citations · Full text

Medicine, Neurology, Movement Disorders +14

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

Pietro Lampertico, Mauro Viganò, G.G. Di Costanzo et al. · Gut · 2012 · 117 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study

Roberto Buzzoni, Sara Pusceddu, Emilio Bajetta et al. · Annals of Oncology · 2014 · 68 citations · Full text

Medicine, Oncology, Chemotherapy +10